{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:41:45Z","timestamp":1792748505739,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kite Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In patients with non-Hodgkin lymphoma (NHL) treated with chimeric antigen receptor (CAR) T cell therapy, factors associated with efficacy overlap with prognostic biomarkers. Currently, there is no consensus on optimal product characteristics. We analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with NHL across multiple clinical trials with long-term follow-up (median, 41.9\u2009months). A high proportion of naive-like (CCR7\n                    <jats:sup>+<\/jats:sup>\n                    CD45RA\n                    <jats:sup>+<\/jats:sup>\n                    ) T cells was the most significant feature associated with prolonged progression-free survival (PFS; hazard ratio\u2009=\u20090.46, 95% confidence interval: 0.31\u22120.68,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20099.8\u2009\u00d7\u200910\n                    <jats:sup>\u22125<\/jats:sup>\n                    , high versus low naive-like T cell groups) without impacting safety. The relationship between naive-like T cells and efficacy was independent of tumor microenvironment characteristics (assessed in 112 patients). In multivariate models, the naive-like phenotype outperformed clinicopathologic features such as inflammatory markers and tumor burden, remaining significant after adjusting for product expansion. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention. The key findings were validated in an independent cohort of 203 patients treated with axi-cel-based therapy or brexucabtagene autoleucel. Mass cytometry by time-of-flight analysis of products from a subgroup of 116 patients confirmed an association between a CD8 naive-like T cell phenotype lacking expression of exhaustion markers, such as TIGIT, LAG-3 and PD-1, and PFS. The evidence generated by this study has the potential to advance the development of more effective cellular therapies.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04707-w","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:01:29Z","timestamp":1792746089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-1508","authenticated-orcid":false,"given":"Justin","family":"Budka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-8974","authenticated-orcid":false,"given":"Madison","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Margaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Vardhanabhuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Arihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Mattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-773X","authenticated-orcid":false,"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"4707_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4707_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4707_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4707_CR4","doi-asserted-by":"publisher","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant. Cell. Ther. 28, 581.e1\u2013581.e8 (2022).","journal-title":"Transplant. Cell. Ther."},{"key":"4707_CR5","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4707_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/hon.3164_271","volume":"41","author":"C Jacobson","year":"2023","unstructured":"Jacobson, C. et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL). Hematol. Oncol. 41, 375\u2013376 (2023).","journal-title":"Hematol. Oncol."},{"key":"4707_CR7","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1200\/JCO-25-00668","volume":"43","author":"SS Neelapu","year":"2025","unstructured":"Neelapu, S. S. et al. Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma. J. Clin. Oncol. 43, 3573\u20133577 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4707_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","volume":"5","author":"RG Faramand","year":"2024","unstructured":"Faramand, R. G. et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 5, 106\u2013113 (2024).","journal-title":"Blood Cancer Discov."},{"key":"4707_CR9","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"4707_CR10","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1182\/blood.2023021620","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood 143, 2464\u20132473 (2024).","journal-title":"Blood"},{"key":"4707_CR11","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"key":"4707_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","volume":"31","author":"SS Raj","year":"2025","unstructured":"Raj, S. S. et al. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat. Med. 31, 1183\u20131194 (2025).","journal-title":"Nat. Med."},{"key":"4707_CR13","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1182\/blood-2024-193598","volume":"144","author":"S Saowapa","year":"2024","unstructured":"Saowapa, S. et al. Ferritin level as a prognostic marker for non-Hodgkin lymphoma: a systematic review and meta-analysis. Blood 144, 6448 (2024).","journal-title":"Blood"},{"key":"4707_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-020-02910-0","volume":"112","author":"Y Kawaguchi","year":"2020","unstructured":"Kawaguchi, Y. et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy. Int. J. Hematol. 112, 341\u2013348 (2020).","journal-title":"Int. J. Hematol."},{"key":"4707_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn, L. H. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857\u20131861 (2007).","journal-title":"Blood"},{"key":"4707_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao, Z. et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 14, 213 (2024).","journal-title":"Blood Cancer J."},{"key":"4707_CR17","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"4707_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"4707_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"key":"4707_CR20","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"4707_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ccell.2023.08.015","volume":"41","author":"X Li","year":"2023","unstructured":"Li, X. et al. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41, 1835\u20131837 (2023).","journal-title":"Cancer Cell"},{"key":"4707_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli, E. et al. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br. J. Haematol. 203, 564\u2013570 (2023).","journal-title":"Br. J. Haematol."},{"key":"4707_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"4707_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto, F. et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708\u2013712 (1999).","journal-title":"Nature"},{"key":"4707_CR25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell\u2013like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"4707_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41577-025-01238-2","volume":"26","author":"D Masopust","year":"2026","unstructured":"Masopust, D. et al. Guidelines for T cell nomenclature. Nat. Rev. Immunol. 26, 298\u2013313 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"4707_CR27","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2026.03.047","volume":"189","author":"L Gattinoni","year":"2026","unstructured":"Gattinoni, L. et al. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell 189, 3686\u20133700 (2026).","journal-title":"Cell"},{"key":"4707_CR28","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"4707_CR29","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/bloodadvances.2024013146","volume":"8","author":"AC Lionel","year":"2024","unstructured":"Lionel, A. C. & Neelapu, S. S. CAR T-cell expansion: harmful or helpful? Blood Adv. 8, 3311\u20133313 (2024).","journal-title":"Blood Adv."},{"key":"4707_CR30","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"4707_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med. 30, 507\u2013518 (2024).","journal-title":"Nat. Med."},{"key":"4707_CR32","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-24-2267","volume":"31","author":"A Hijazi","year":"2025","unstructured":"Hijazi, A. et al. Facts and hopes: CAR T-cell therapy and immune contexture in non-Hodgkin lymphoma. Clin. Cancer Res. 31, 3834\u20133843 (2025).","journal-title":"Clin. Cancer Res."},{"key":"4707_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"4707_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"4707_CR35","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.4049\/jimmunol.1901072","volume":"203","author":"G De Simone","year":"2019","unstructured":"De Simone, G. et al. CXCR3 identifies human naive CD8+ T cells with enhanced effector differentiation potential. J. Immunol. 203, 3179\u20133189 (2019).","journal-title":"J. Immunol."},{"key":"4707_CR36","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J. Clin. Oncol. 38, 3095\u20133106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4707_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni1238","volume":"6","author":"GF Debes","year":"2005","unstructured":"Debes, G. F. et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 6, 889\u2013894 (2005).","journal-title":"Nat. Immunol."},{"key":"4707_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101053","volume":"4","author":"IY Jung","year":"2023","unstructured":"Jung, I. Y. et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep. Med. 4, 101053 (2023).","journal-title":"Cell Rep. Med."},{"key":"4707_CR39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"4707_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"4707_CR41","doi-asserted-by":"publisher","first-page":"TPS7098","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS7098","volume":"44","author":"S Dahiya","year":"2026","unstructured":"Dahiya, S. et al. KITE-753: a phase 2 study of an autologous anti-CD19\/CD20 CAR T-cell therapy in CAR-naive patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL). J. Clin. Oncol. 44, TPS7098 (2026).","journal-title":"J. Clin. Oncol."},{"key":"4707_CR42","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1182\/blood.2024026758","volume":"145","author":"AC Caballero","year":"2025","unstructured":"Caballero, A. C. et al. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma. Blood 145, 1788\u20131801 (2025).","journal-title":"Blood"},{"key":"4707_CR43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001\u20131012 (2024).","journal-title":"Nat. Med."},{"key":"4707_CR44","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","volume":"29","author":"I Aldoss","year":"2023","unstructured":"Aldoss, I. et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor t-cell therapy in adults with high-risk relapsed\/refractory ALL. Clin. Cancer Res. 29, 742\u2013753 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4707_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","volume":"13","author":"SM Larson","year":"2023","unstructured":"Larson, S. M. et al. CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov. 13, 580\u2013597 (2023).","journal-title":"Cancer Discov."},{"key":"4707_CR46","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.jcyt.2024.03.259","volume":"26","author":"A Jain","year":"2024","unstructured":"Jain, A. et al. Harnessing potent na\u00efve like t cells for precision CAR T manufacturing. Cytotherapy 26, S135 (2024).","journal-title":"Cytotherapy"},{"key":"4707_CR47","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","volume":"6","author":"A Cuffel","year":"2022","unstructured":"Cuffel, A. et al. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 6, 4657\u20134660 (2022).","journal-title":"Blood Adv."},{"key":"4707_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"4707_CR49","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen, G. M. et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 11, 2186\u20132199 (2021).","journal-title":"Cancer Discov."},{"key":"4707_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41551-026-01633-7","volume":"10","author":"GM Chen","year":"2026","unstructured":"Chen, G. M. et al. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat. Biomed. Eng. 10, 803\u2013814 (2026).","journal-title":"Nat. Biomed. Eng."},{"key":"4707_CR51","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transplant. Cell. Ther. 30, 1065\u20131079 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"4707_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u22122 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"4707_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690\u2013700 (2021).","journal-title":"Br. J. Haematol."},{"key":"4707_CR54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp, M. S. et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 195, 388\u2013398 (2021).","journal-title":"Br. J. Haematol."},{"key":"4707_CR55","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","volume":"59","author":"OO Oluwole","year":"2024","unstructured":"Oluwole, O. O. et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 59, 366\u2013372 (2024).","journal-title":"Bone Marrow Transplant."},{"key":"4707_CR56","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"4707_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4707_CR58","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"key":"4707_CR59","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.2024027347","volume":"145","author":"JC Chavez","year":"2025","unstructured":"Chavez, J. C. et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood 145, 2303\u20132311 (2025).","journal-title":"Blood"},{"key":"4707_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"4707_CR61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J. Clin. Oncol. 41, 555\u2013567 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4707_CR62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-026-01797-4","volume":"19","author":"J Mu\u00f1oz","year":"2026","unstructured":"Mu\u00f1oz, J. et al. Five-year follow-up of patients with relapsed\/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J. Hematol. Oncol. 19, 39 (2026).","journal-title":"J. Hematol. Oncol."},{"key":"4707_CR63","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood.2025029734","volume":"147","author":"T van Meerten","year":"2026","unstructured":"van Meerten, T. et al. Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3. Blood 147, 1302\u20131314 (2026).","journal-title":"Blood"},{"key":"4707_CR64","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1158\/1078-0432.CCR-25-0602","volume":"32","author":"CA Jacobson","year":"2026","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in combination with atezolizumab in patients with refractory diffuse large B-cell lymphoma: the phase 1\/2 ZUMA-6 trial. Clin. Cancer Res. 32, 894\u2013904 (2026).","journal-title":"Clin. Cancer Res."},{"key":"4707_CR65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s43018-025-01102-1","volume":"7","author":"P Strati","year":"2026","unstructured":"Strati, P. et al. Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial. Nat. Cancer 7, 304\u2013315 (2026).","journal-title":"Nat. Cancer"},{"key":"4707_CR66","doi-asserted-by":"publisher","first-page":"e001619","DOI":"10.1136\/jitc-2020-001619","volume":"8","author":"E Wang","year":"2020","unstructured":"Wang, E., Cesano, A., Butterfield, L. H. & Marincola, F. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. J. Immunother. Cancer 8, e001619 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4707_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"4707_CR68","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1038\/cti.2014.16","volume":"3","author":"JK Flynn","year":"2014","unstructured":"Flynn, J. K. & Gorry, P. R. Stem memory T cells (TSCM)\u2014their role in cancer and HIV immunotherapies. Clin. Transl. Immunology 3, e20 (2014).","journal-title":"Clin. Transl. Immunology"},{"key":"4707_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29383-5","volume":"13","author":"CB Pedersen","year":"2022","unstructured":"Pedersen, C. B. et al. cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nat. Commun. 13, 1698 (2022).","journal-title":"Nat. Commun."},{"key":"4707_CR70","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","volume":"6","author":"S Chevrier","year":"2018","unstructured":"Chevrier, S. et al. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 6, 612\u2013620 (2018).","journal-title":"Cell Syst."},{"key":"4707_CR71","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"4707_CR72","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04707-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:01:30Z","timestamp":1792746090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04707-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":72,"alternative-id":["4707"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04707-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B., M.D., S.V., C.W., S.P., M.M., P.H., D.M.B., R.S., S.F., S.C., J.D., J.M., W.Z., J.W. and D.B. are employees of Kite, a Gilead Company. J.B., M.D., S.V., C.W., S.P., M.M., P.H., D.M.B., R.S., S.F., S.C., J.D., J.M., W.Z., J.W. and D.B. hold equity in Gilead Sciences. P.H. serves on the Board of Directors of Adaptimmune. D.B. owns stock in Immunomica s.r.l. R.S. holds patents and receives royalties from Atara. S.F. has intellectual property interests with Tusk Therapeutics. S.P. holds patents and receives royalties from the University of California, Los Angeles (UCLA). S.V. has received research funding from Kite, a Gilead Company. J.R. holds stock in CGT Global.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}